Results 171 to 180 of about 187,044 (318)

Adrenaline auto injectors pharmacokinetic/pharmacodynamic studies and potential consequences for clinical practice [PDF]

, 2023
Margitta Worm, Adam Fox, Magnus Wickman, Johannes Ring, Motohiro Ebisawa, Guillaume Pouessel, Peter Smith   +6 more
openalex   +1 more source

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses.
Sooyoun Lee, Hyun Chul Kim, Young Ran Yoon, In‐Jin Jang, Sang‐Ku Yoo, Kyung‐Sang Yu   +5 more
wiley   +1 more source

Evaluation of pharmacokinetics and pharmacodynamics relationships for Salvianolic Acid B micro-porous osmotic pump pellets in angina pectoris rabbit

, 2014
Shu-Ling Kan, Jin Li, Jianping Liu, Hongliang He, Wenjing Zhang   +4 more
openalex   +1 more source

Human vs. artificial intelligence: Physicians outperform ChatGPT in real‐world pharmacotherapy counselling

British Journal of Clinical Pharmacology, EarlyView.
Aims To assess the utility of the artificial intelligence (AI) chatbot ChatGPT (openly available version 3.5) in responding to real‐world pharmacotherapeutic queries from healthcare professionals. Methods Three independent and blinded evaluators with different levels of medical expertise and professional experience (beginner, advanced, and expert ...
Benjamin Krichevsky, Stefan Engeli, Stefanie M. Bode‐Böger, Felix Koop, Martin Schulze Westhoff, Sebastian Schröder, Carsten Schumacher, Thorben Pape, Dirk O. Stichtenoth, Johannes Heck   +9 more
wiley   +1 more source

Correction to: An automated pipeline to generate initial estimates for population Pharmacokinetic base models. [PDF]

J Pharmacokinet Pharmacodyn
Huang Z, Fidler M, Lan M, Cheng IL, Kloprogge F, Standing JF.   +5 more
europepmc   +1 more source

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled ...
Jean‐Yves Gillon, Sophie Delhomme, Delphine Launay, Séverine Blesson, Stéphanie Braillard, Pegah Maghdooni, Frauke Assmus, Richard Hoglund, Joel Tarning, Sabrina Loyau, Byron Arana, Mathilde Latreille‐Barbier, Yves Donazzolo   +12 more
wiley   +1 more source

Pharmacodynamics of Daptomycin in a Murine Thigh Model of Staphylococcus aureus Infection

, 2001
Arnold Louie, Pamela Kaw, Weiguo Liu, Nelson L. ‘Shasha’ Jumbe, Michael H. Miller, George L. Drusano   +5 more
openalex   +1 more source

Pharmacodynamics and pharmacokinetics of ketoprofen enantiomers in sheep [PDF]

, 2001
Abdul K. Arifah, M. F. Landoni, Stephen P. Frean, P. Lees   +3 more
openalex   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source

Salmeterol inhaler using a non-chlorinated propellant, HFA134a: systemic pharmacodynamic activity in healthy volunteers. [PDF]

, 1995
Suzanne Kirby, John A. Smith, G P Ventresca   +2 more
openalex   +1 more source